The cancer drug developed by GSK significantly reduces the risk of death in patients, tests have shown.
The major pharmaceutical company’s Blenrep treatment was shown in a study to reduce the risk of death by 42 percent for those suffering from multiple myeloma, a type of bone marrow cancer.
Although the disease cannot be cured, the data showed that patients taking Blenrep lived almost three years longer than those using current treatments.
The results are a boost for GSK and CEO Emma Walmsley (pictured), who are trying to improve the pipeline of new drugs and vaccines.
Blenrep could be worth more than £3 billion in annual sales for GSK if it comes to market.
The drug has been approved for a key review by Chinese regulators after a similar move last month by US regulators.
Trial success: GSK boss Emma Walmsley (pictured), trying to improve the pipeline of new drugs and vaccines.
DIY PLATFORMS Investing
AJ Bell
AJ Bell
Flexible and ready-made accounts
Hargreaves Lansdowne
Hargreaves Lansdowne
Free money making and investment ideas
interactive sender
interactive sender
Investment costs from £4.99 per month
Saxo
Saxo
Get £200 back on shopping fees
Trade 212
Trade 212
Free work and no deposit
Affiliate link: If you download a product This Money earns a commission. These prices are selected by our editorial team, because we think they are worth celebrating. This does not affect our independence.
